Lung Cancer Clinical Trial
F18-FDG is the widely used PET tracer in the routine practice of oncologic disease imaging
using the technology of PET-CT. However, FDG-avidity is a characteristic of the individual
tumor. There are various types of human malignancies, which are not taking FDG in access. In
these cases FDG is not a sensitive tracer of imaging. In search for other tumor PET tracers,
C11-Acetate has been shown recently in a few early studies to have a potential value in
imaging of non-FDG-avid tumors.
The purpose of the current study is to assess the role of 11C-acetate PET in various tumors,
which often are not detected by 18F-FDG and were not widely assessed until now.
Recent publications have suggested the use of 11C-acetate as another PET tracer for tumor
imaging. The accumulation of 11C-acetate in tumor cells is related to the highly active
lipid metabolism in the cell membrane associated with tumor growth. 11C-acetate is channeled
into the tricarboxylic acid cycle via acetyl coenzyme A and then incorporated via
phosphatidylcholine into the cell membrane's phopholipids. Possible biochemical paths of
acetate incorporation or accumulation include (a) entering the Krebs cycle from acetyl
coenzyme A (acetyl CoA) or as an intermediate metabolite, (b) esterification to form acetyl
CoA as a major precursor in ß-oxidation for fatty acid synthesis, (c) combining with glycine
in heme synthesis, and (d) through citrate for cholesterol synthesis. Of all of these
possible metabolic pathways, participation in free fatty acid (lipid) synthesis is believed
to be the dominant method of incorporation in tumors.
The clinical data on the role of 11C-acetate PET in human tumors is being accumulated. Most
clinical studies have investigated the role of 11C-acetate PET in detection of prostate
cancer. 11C-acetate PET was found valuable in the detection of recurrent prostate cancer,
both in the prostate bed, lymph nodes and distant metastases. The main advantage of
11C-acetate is that it does not show physiological accumulation in the urinary bladder as is
the case with 18F -FDG and therefore may be appropriate for the detection of active pelvic
disease.
Comparing the uptake of 18F-FDG and of 11C-acetate in patients with lung carcinoma, the
latter was found superior in the identification of a bronchiolo-alveolar carcinoma which
often show no intense FDG uptake.
In the case of hepatic masses, well-differentiated HCC tumors were detect by 11C-acetate
while poorly differentiated types were detected by 18F-FDG.
These data suggest that 11C-acetate PET may be valuable in the detection of
well-differentiation slow growing tumors and may have a complementary role to the routinely
used 18F-FDG.
;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
| Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
| Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
| Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
| Active, not recruiting |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
| Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
| Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
| Recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
| Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
| Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
| Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
| Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
| Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
| Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|